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Abstract
Background: The immune response during P. falciparum infection is a two-edged sword, involving dysregulation of the
inflammatory responses with several types of immune cells participating. Here we examined T-cell, monocyte/macrophage
and neutrophil activation during P. falciparum infection by using soluble activation markers for these leukocyte subsets.
Methods: In a prospective cross-sectional study clinical data and blood samples were collected from adults in
Mozambique with P. falciparum infection, with (n= 70) and without (n= 61) co-infection with HIV-1, as well as HIV-infected
patients with similar symptoms but without malaria (n= 58) and healthy controls (n= 52). Soluble (s)CD25, sCD14, sCD163
and myeloperoxidase (MPO) as markers for T-cell, monocyte/macrophage and neutrophil activation, respectively as well as
CX3CL1, granzyme B and TIM-3 as markers of T-cell subsets and T-cell exhaustion, were analyzed.
Results: All patient groups had raised levels of activation markers compared with healthy controls. Levels of sCD25 and
MPO increased gradually from patient with HIV only to patient with malaria only, with the highest levels in the HIV/malaria
group. In the malaria group as a whole, MPO, sCD14 and in particular sCD25 were correlated with disease severity. sCD163,
sCD25 and in particular MPO correlated with the degree of parasitemia as assessed by qPCR. Patients with falciparum
malaria also had signs of T-cell subset activation (i.e. increased granzyme B and CX3CL1) and T-cell exhaustion as assessed
by high levels of TIM-3 particularly in patients co-infected with HIV.
Conclusion: Our data support a marked immune activation in falciparum malaria involving all major leukocyte subsets with
particular enhanced activation of neutrophils and T-cells in patients co-infected with HIV. Our findings also support a link
between immune activation and immune exhaustion during falciparum malaria, particularly in relation to T-cell responses
in patients co-infected with HIV.
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Background
Infection with Plasmodium falciparum (P. falciparum) is
associated with a marked increase in systemic inflamma-
tion. Whereas this immune activation could contribute to
parasite clearance, an enhanced immune response could
also contribute to disease progression by promoting tissue
damage rather than protection and through induction of
immune exhaustion [1]. The immune response during P.
falciparum infection involves several immune cells as well
as their interactions. Thus, P. falciparum infection is associ-
ated with a profound T-cell activation with the Th1-derived
cytokine interferon γ as a major pathogenic factor [2, 3].
Monocytes/macrophages are one of the main sources of cy-
tokines in malaria-infected individuals and whereas some
of these may be of importance for parasite clearance (e.g.,
interleukin 12) [4], others may be major players in disease
progression (e.g., tumor necrosis factor) [5]. Moreover,
whereas the inflammatory M1 macrophages could
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contribute to a sustained and harmful inflammation during
P. falciparum infection, the anti-inflammatory and
pro-resolving M2 macrophages may prevent the develop-
ment of overt disease. Neutrophils are the most abundant
leukocyte population in the bloodstream, the primary com-
partment of P. falciparum, and several studies support a
role of these cells in P. falciparum infection [6–8]. The re-
lease of proteases and myeloperoxidase (MPO) could con-
tribute to tissue damage and parasite invasion, whereas the
formation of neutrophil extracellular traps (NETs) could
contribute to parasite clearance.
There are several studies on immune activation and in-
flammation during P. falciparum infection, and some of
these have also examined T-cells, monocytes/macrophages
and neutrophils [9–12], but the role of these cells during
falciparum malaria are far from clear. In particular, most
studies have focused on one of these cell subsets, and
fewer have examined the activation pattern of these cells
simultaneously. In the present study we aimed to study
the activation of T-cells, monocytes/macrophages and
neutrophils during infection with P. falciparum by using
sCD25, sCD14, sCD163 and MPO as markers of T-cell,
monocyte/macrophage and neutrophil activation, respect-
ively. Moreover, whereas sCD163 at least to some degree
could reflect M2 activity [13], sCD14 is regarded as a
more overall marker of monocytes/macrophage activation.
Levels of these markers were related to the degree of para-
sitemia as assessed by quantitative PCR measurements as
well as disease severity. The study was performed in
Mozambique that has one of the highest global incidences
of co-infection with HIV and falciparum malaria.
Co-infection with those two infections poses an increased
risk of severe malaria disease [14]. We therefore also ex-
amined how HIV infection influenced plasma levels of
sCD25, sCD14, sCD163 and MPO in these patients.
Materials and methods
Description of study design and participants
The study design has previously been described [14] and the
clinical characteristics of the patient groups are given in
Table 1. Briefly, in this prospective, cross-sectional study, we
included 212 patients admitted into the Medical Emergency
Department in the Central Hospital of Maputo,
Mozambique during seven months in two malaria peak sea-
sons, from 2011 to 2012. Inclusion criteria were age ≥ 18
years, non-pregnancy, axillary temperature ≥ 38 °C and/or
clinical suspected or confirmed malaria infection, and con-
sent from patient or next of kin. Of the 212 screened pa-
tients, 131 had P. falciparum malaria as assessed by
qualitative PCR (n = 129) or antigen test/slides (n = 2), giving
a total of 131 malaria patients. Two patients had in addition
double-infection with P. vivax and with P. malariae, re-
spectively. In the malaria patients, the median age was 37
years (18–84 years), 47% were women, and 53% were
co-infected with HIV-1 as assessed by PCR and/or sero-
logical tests. For comparison we also included 58
HIV-1-infected patients with suspected, but excluded, mal-
aria. Fifty-two apparently healthy HIV seronegative and mal-
aria negative volunteers with median age 26 years (18–56
years), 41% women, were recruited from hospital employees.
Of the patients 65% [85/131] had severe malaria and
13% [17/131] had very severe malaria, defined as the
presence of ≥1 and ≥ 3 malaria severity criteria, respect-
ively, modified from the World Health Organization
[15]. Of the malaria patients 7.6% died (10/128, missing
data on outcome in 3 patients).
Collection of blood samples and preparation of plasma
and serum from patients and controls
Blood samples from patients and healthy controls were col-
lected from a pre-alcohol-cleaned peripheral vein into
pyrogenic-free tubes with or without EDTA. Plasma tubes
were placed immediately on ice, and centrifuged within 30
min at 2000 g for 20min to obtain plasma. Serum samples
were allowed to clot for 30min at room temperature before
centrifugation for 10min at 1000 g. Plasma and serum was
aliquoted and stored at − 20 °C for 24 h; then at -80 °C.
Samples were thawed only once.
The qualitative P. falciparum PCR in whole blood
Qualitative malaria PCR was performed from the blood
cell fraction with the use of malaria plasmodium mito-
chondria- and species specific 18S PCR, and divergent
results were resolved by DNA sequencing [16].
Table 1 Clinical characteristicsa) of the patient populationb)
N HIV only Malaria only Malaria & HIV
58 61 70
Age, years 39 (22–84) 40 (18–79) 40 (20–65)
Sex, females 50 (29/58) 41 (25/61) 50 (35/70)
Hemoglobin (g/dL) 8.9 (2.9–15.2) 11.2 (3.2–17.0) 9.4 (2.5–15.7)
Leukocytes (× 109/L) 8.2 (0.3–25.4) 6.9 (1.3–15.5) 7.8 (0.9–21.8)
Platelets (×109/L) 220 (13–682) 124 (11–452) 90 (8–330)
Se-Creatinine (μmol/L) 161 (41–873) 127 (57–357) 223 (62–1529)
Se-Glucosis (mmol/L) 6.1 (3.3–10.6) 8.7 (3.6–40.5) 6.12 (1.5–27.0)
Liverfailurec) 5 (4/57) 5 (3/61) 19 (13/70)
Coagulation disturb.d) 0 2 (1/61) 13 (9/70)
Cerebral disturb. e) 33 (19/58) 25 (15/61) 31 (22/70)
Systolic blood pressure 115 (90–160) 122 (70–240) 115 (80–170)
Respiratory rate 29 (12–56) 22 (12–68) 24 (16–42)
Case fatality rate 27.8 (15/54) 1.7 (1/59) 13.0f) (9/69)
a) Values in mean (min-max) or percentage and proportion
b) The 52 healthy controls are not included
c) Defined as jaundice/ bilirubine> 43 μmol/L
d) Defined as bleeding disturbances/ hemolysis
e) Defined as GCS ≤ 11, convulsions or confusion
f) One patient died of non-malarial cause, he is excluded
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The quantitative P. falciparum PCR in plasma
The concentration of P. falciparum DNA in plasma was
measured by quantitative real-time PCR (qPCR) as de-
scribed [17] using Primer Pf-1 (5′-ATT GCT TTT GAG
AGG TTT TGT TAC TTT-3′), primer Pf-2 (5’-GCT
GTA GTA TTC AAA CAC AAT GAA CTC AA-3′) and
probe Pf (5’-CAT AAC AGA CGG GTA GTC AT-3′)
(Applied Biosystems, Cheshire, UK). All samples were run
on LightCycler® 480 Multiwell Plate 384, white (Roche
Diagnostics, Mannheim, Germany), and sealed with Light-
Cycler® 480 Sealing Foil (Roche). Each run included a
positive control and multiple no-template controls. DNA
extracted from an external reference material P. falcip-
arum (US 03 F Benin I), containing exclusively ring stage
parasites in a concentration of 2000 p/μl, was used for
dilution series, five-fold, to prepare standard curve for
estimating efficiency of the PCR and for quantification.
Measurements of cytokines and markers of inflammation
Plasma levels of MPO, sCD14, sCD163, granzyme B,
CX3CL1 (fractalkine) and TIM-3 (T cell immunoglobu-
lin and mucin domain 3) and serum levels of sCD25
were measured by enzyme linked immunosorbent assay
(ELISA) in duplicate using commercially available anti-
bodies (R&D Systems, Minneapolis, MN, USA) in a 384
format using the combination of a SELMA (Jena,
Germany) pipetting robot and a BioTek (Winooski, VT,
USA) dispenser/washer (EL406). Absorption was read at
450 nm with wavelength correction set to 540 nm using
an ELISA plate reader (Synergy H1 Hybrid, Biotek,
Vinooski, VT, USA). The intra- and interassay coefficient
of variation were < 10% for all assays.
Statistical analyses
The distribution of each leukocyte marker was skewed
and nonparametric statistics were used throughout. For
comparison between the diagnostic groups, Kruskal
Wallis was used a priori followed by Dunn’s multiple
comparison test between individual groups. Wilcoxon
matched-pairs signed rank test was used to compare
changes from baseline to follow-up within each diagnos-
tic group. Spearman correlation was used to assess asso-
ciations between variables. A two-sided p < 0.05 was
considered significant.
Results
MPO, sCD25, sCD14 and sCD163 in P. falciparum infection
with and without HIV infection
As can be seen in Fig. 1, all soluble markers of leukocyte
activation were markedly increased in all groups of pa-
tients (HIV without malaria [n = 58], and malaria with [n
= 70] and without [n = 61] HIV) as compared with healthy
controls (n = 52). However, some differences were revealed
between the different markers. First, sCD25, reflecting
T-cell activation, and MPO, reflecting neutrophil activa-
tion, showed a gradual increase from the group with iso-
lated HIV infection to the group with malaria and with
the highest levels in the group with HIV and malaria
co-infection. Second, as for the monocyte markers sCD14
and sCD163, the differences between the three patient
groups were modest with the difference in sCD14 between
malaria with and without HIV infection as the only signifi-
cant finding (Fig. 1).
Soluble markers of leukocyte activation during follow-up
In 77 patients (HIV without malaria [n = 49], malaria only
[n = 6], malaria and HIV [n = 22]) we also had follow-up
samples taken in hospital after 48 h (Fig. 2). All four
markers of leukocyte activation were markedly increased
during follow-up in all three groups of patients as com-
pared to healthy controls, despite some decline during
follow-up. In HIV-infected patients co-infected with P. fal-
ciparum there was a significant decline in MPO, sCD25
and sCD14 levels during follow-up, and for MPO, this was
also seen for malaria patients without HIV infection. No
changes in these markers were seen during follow-up for
HIV-infected patients without malaria. None of the three
patient groups showed any significant changes for sCD163.
MPO, sCD25, sCD14 and sCD163 in relation to clinical
disease severity
In the malaria group as a whole (n = 131), both MPO (r
= 0.19, p = 0.03), sCD14 (r = 0.24, p = 0.006) and in par-
ticular sCD25 (r = 0.29, p = 0.001), but not sCD163 (r =
0.15, p = 0.1), were correlated with disease severity as
assessed by the WHO definition [15], with the strongest
correlation for sCD14 (r = 0.33, p = 0.011) in those with-
out HIV infection (n = 61), and for sCD25 (r = 0.27, p =
0.022) in those with HIV co-infection (n = 70) (Table 2).
MPO, sCD25, sCD14 and sCD163 in relation to the degree
of malaria parasitemia
In 93 of the malaria patients, the degree of malaria parasit-
emia could be assessed by qPCR (39 patients had levels
below the detection limit of the assay). As shown in Fig. 3,
sCD163, sCD25 and in particular MPO levels, but not
sCD14 levels, were strongly correlated with the degree of
parasitemia. For sCD25 and MPO, the same patterns were
seen when those with (n= 49) and without (n= 44)
co-infection with HIV were analysed separately (Additional
file 1: Table S1).
Markers of T-cell subset activation and T-cell exhaustion
during falciparum malaria
In order to further characterize the T-cell response dur-
ing falciparum malaria we measured granzyme B as a
marker of activated CD8+ T-cells [18] and TIM-3 that
could promote induction of effector memory T-cells
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[19]. Moreover, CX3CL1 could potentially promote
differentiation into T effector cells (Teff ), a cell type that
has high expression of CX3CR1 [20], and could there-
fore at least indirectly be related to these T-cell subsets.
T-cell exhaustion is an important feature of severe mal-
aria [1] and granzyme B [21] and in particular TIM-3
[22] could also be markers of this process. As seen in
Fig. 4, malaria patients had increased plasma levels of
granzyme B and CX3CL1 as compared with
HIV-infected patients without malaria with no difference
between those with and without co-infection with HIV.
Moreover, TIM-3 levels were also markedly increased
during falciparum malaria as compared with
HIV-infected patients without malaria, and notably,
malaria patients co-infected with HIV had particular
high levels of TIM-3 (Fig. 4).
Fig. 1 Levels of soluble leukocyte activation markers in patients. Plasma/serum levels of MPO (a), sCD25 (b), sCD14 (c) and sCD163 (d) in patients
with HIV infection without malaria (n = 58), patients with falciparum malaria without (n = 61) and with HIV infection (n = 70). Data are given as
median and 25-75th percentiles. **p < 0.01 and ***p < 0.001 versus HIV without malaria. †p < 0.05 versus falciparum malaria without HIV. The
horizontal grey shaded area represent levels 25-75th percentiles in age- and sex-matched healthy controls (n = 52). In all three groups of patients,
all parameters were significantly raised compared with levels in controls (p < 0.001 for all comparisons)
Fig. 2 Levels of soluble leukocyte activation markers at admission and follow-up. Plasma/serum levels of MPO (a), sCD25 (b), sCD14 (c) and
sCD163 (d) in patients with HIV infection without malaria (n = 49), patients with falciparum malaria without (n = 6) and with HIV infection (n = 22)
at admission (before) and 48 h thereafter (after). Data are given as median and 25-75th percentiles. **p < 0.01 and ***p < 0.001 versus levels at
admission. The horizontal grey shaded area represent levels 25-75th percentiles in age- and sex-matched healthy controls (n = 52). In all three
groups of patients, all parameters were significantly raised compared with levels in controls both at admission and during follow-up (p < 0.001 for
all comparisons)
Otterdal et al. BMC Infectious Diseases          (2018) 18:670 Page 4 of 8
Discussion
Infection with P. falciparum is characterized by a marked
immune activation that may be both beneficial (i.e.,
anti-parasitic) and harmful (i.e., tissue destruction) for the
host. We have previously demonstrated an approximately
30-fold increase in interferon inducing protein (IP-10) levels
compared with healthy controls in this population of patients
with falciparum malaria [23] indicating a marked immune
response affecting T-cell activation in these patients. Herein
we extend these findings by showing enhanced activation of
neutrophils, T-cells and monocyte/macrophages as assessed
by the soluble activation markers MPO, sCD25, sCD14 and
sCD163, with particular high levels of MPO and sCD25 in
malaria patients that were co-infected with HIV. MPO,
sCD25 and sCD14 were significantly correlated with clinical
disease severity and sCD25 and in particular MPO were also
strongly associated with degree of parasitemia as assessed by
quantitative P. falciparum PCR in plasma. Finally, patients
with falciparum malaria also had elevated plasma levels of
granzyme B and CX3CL1 suggesting enhanced activation of
CD8+ T-cells and effector memory T-cell subsets, and the
marked increase in TIM-3 suggest some degree of T-cell ex-
haustion during falciparum malaria particularly in those
co-infected with HIV. Our findings further underscore the
link between immune activation and immune exhaustion
during severe falciparum malaria potentially contributing to
disease severity.
MPO and neutrophils have been implicated in the
pathogenesis of falciparum malaria. A recent study of
Plasmodium yoelii non-lethal infection in wild-type and
MPO deficient mice as a murine malaria model, sug-
gested that MPO could contribute to a protective
anti-parasite response [24]. However, very few studies
have analyzed MPO levels in human falciparum malaria.
Recently, Rocha et al. showed that circulating neutro-
phils from malaria patients are highly activated, as indi-
cated by a strong type I interferon transcriptional
signature, increased expression of surface activation
markers, enhanced release of ROS and MPO, associated
with increased liver damage [25]. Herein we show a
Table 2 Correlation between disease severity and leukocyte
activation markers in patients with (n = 70) and without (n = 61) HIV
Malaria Malaria + HIV
sCD14 0.33a(0,011) 0.08 (0,533)
sCD25 0.23 (0,079) 0.27a (0,022)
MPO 0.13 (0,316) 0.21 (0,078)
sCD163 0.05 (0,704) 0.17 (0,175)
aCorrelation is significant at the 0.05 level (2-tailed)
Fig. 3 Correlations between soluble leukocyte activation markers and degree of parasitemia. Correlations between MPO (a), sCD25 (b), sCD14 (c)
and sCD163 (d) and the degree of parasitemia could be assessed by quantitative P. falciparum PCR in 93 of the malaria patients (39 patients had
levels below the detection limit of the assay). The figure present data from these 93 patients (49 with and 44 without co-infection with HIV)
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strong association between MPO levels and the degree
of P. falciparum parasitemia as assessed by qPCR
analyses, suggesting that neutrophils and MPO could
promote rather than attenuate parasitemia. Moreover, if
the high MPO levels reflect degranulated and exhausted
neutrophils, the outcome could also be harmful to the
host. MPO release has more recently been related to
NET formation that could have anti-parasitic effects, but
NETs could also promote vascular pathology during
falciparum malaria, illustrating the immune response as
a double edge sword during falciparum malaria [26].
We have previously shown that co-infection with HIV
during falciparum malaria is associated with enhanced in-
flammation, increased malaria severity and death [14, 23].
Several other studies also demonstrate that falciparum mal-
aria is more severe in HIV co-infected patients, in particular
in those with decreased CD4 T-cell counts [27, 28]. Here
we extend these findings by showing that HIV-infected pa-
tients with falciparum malaria have markedly raised levels
of MPO and sCD25 as compared with both malaria pa-
tients without HIV infection and HIV-infected patients
without malaria. Moreover, sCD25 levels were also signifi-
cantly correlated with disease severity in particular in those
co-infected with HIV. These findings suggest that despite
T-cell deficiency, co-infected patients have signs of sus-
tained T-cell activation. In fact, sustained T-cell activation
with increased spontaneous release of inflammatory
markers could itself contribute to immunodeficiency. Thus,
high circulating levels of sCD25 are mostly accompanied by
decreased membrane expression of CD25 on T-cells [29]
resulting in attenuated proliferation and IL-2 release upon
further challenge by additional stimuli in the microenviron-
ment in vivo such as during falciparum malaria. Also, we
found markedly increased TIM-3 levels during falciparum
malaria as compared with HIV-infected patients without
malaria, with the highest levels in those co-infected with
HIV, suggesting some degree of T-cell exhaustion during
falciparum malaria in particular in those co-infected with
HIV. CD8+ T-cell-mediated responses seem to be of major
importance in the anti-parasitic T-cell responses and our
findings of enhanced granzyme B levels could reflect an
anti-malaria effect in these patients. Indeed, very recently
granzyme B was found to contribute to the cytotoxic CD8+
T-cell-mediated killing of P. vivax-infected reticulocytes
[30]. However, granzyme B has also been implicated in the
development of cerebral malaria [31] and the increased
granzyme B levels could also reflect degranulated and
exhausted CD8+ T-cells, further illustrating the dual effects
of the immune response during malaria infection.
Recent studies have demonstrated that monocytes/
macrophages are involved in both protection and immu-
nopathology during malaria infection. Data on sCD14
and sCD163 in human falciparum malaria are, however,
relatively scarce. As for sCD163 most data are in
Fig. 4 Markers of T-cell subsets activation and T-cell exhaustion during falciparum malaria. Plasma levels of TIM-3 (a), granzyme B (GrB) (b) and
fractalkine (CX3CL1) (c) in patients with HIV infection without malaria (n = 58), patients with falciparum malaria without (n = 61) and with (n = 70)
HIV infection. Data are given as median and 25-75th percentiles. **p < 0.01 and ***p < 0.001 versus HIV without malaria. ††p < 0.01 versus
falciparum malaria without HIV. The horizontal grey shaded area represent levels 25-75th percentiles in age- and sex-matched healthy controls (n
= 52). For the malaria with and without HIV infection, all markers were raised compared with levels in controls (p < 0.001). For the HIV group
without malaria, TIM-3 but not GrB or CX3CL1, was raised compared to controls (p < 0.001)
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children and in pregnant women showing some associ-
ation with disease severity and birth weight in offspring
of pregnant women [32]. Herein, all three groups (HIV
infection only, falciparum malaria only, combined HIV/
malaria infection) had elevated sCD14 and sCD163
levels with only minor differences between the groups.
As for sCD14, however, we found that patients with fal-
ciparum malaria and HIV had higher levels than those
with malaria alone, and sCD14 was also associated with
clinical disease severity in the malaria group as a whole.
Moreover, we found a significant association between
sCD163 and the degree of parasitemia. The interpret-
ation of these later data is difficult and could be by
chance, but it could also be speculated that an increased
anti-inflammatory M2 response could enhance parasit-
emia. Our data suggest the involvement of monocyte/
macrophage activation during human P. falciparum mal-
aria, but the modest changes and the lack of differences
in sCD14 between febrile HIV-infected patients and
malaria patients suggests that these data should be inter-
preted with caution.
The present study has some limitations such as potential
selection bias of not including the poorest and the wealthi-
est patients, lack of CD4 cell count on several HIV-infected
patients and even if most patients were severely ill, rela-
tively few died, and the sample sizes are too low to probe
associations with mortality. Moreover, correlation analyses
do not necessarily mean any causal relationship. Also,
soluble markers are only surrogate markers of leukocyte ac-
tion and may not fully reflect their activation status. In rela-
tion to T-cell exhaustion, we should ideally have isolated
T-cells from fresh patient samples and investigated re-
sponses like loss of IL-2 production, loss of proliferative
capacity along with co-expression of inhibitory receptors
like PD-1 and CTLA-4 [33] Also, stronger diagnostic tools
than measurements of sCD163, such as flow cytometry and
functional studies in addition to mRNA analyses of isolated
monocytes/macrophages are needed to discriminate be-
tween M1 and M2 macrophages.
Conclusions
Our findings support that falciparum malaria is character-
ized by a marked immune activation involving all major
leukocyte subsets, i.e. T-cells, monocytes/macrophages
and neutrophils, with particular enhanced activation of
neutrophils and T-cells in patients that were co-infected
with HIV. Our findings also support a link between im-
mune activation and immune exhaustion during falcip-
arum malaria, particular in relation to T-cell responses in
patients co-infected with HIV. Future research in this area
should more precisely examine these issues and such
clinical studies need to include analyses of leukocyte cell
subsets isolated from patients with falciparum malaria in
addition to serum and plasma samples.
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